Analyzing outcomes in prostate cancer patients with rare genetic mutations
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes
This study is testing how prostate cancer patients with rare genetic mutations respond to treatment compared to those without these mutations to find better ways to manage their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4260 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Institute of Cancer Research, United Kingdom Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Sutton, Surrey) |
| Trial ID | NCT02705846 on ClinicalTrials.gov |
What this trial studies
GENPROS aims to analyze the outcomes of prostate cancer patients who carry rare gene mutations, such as BRCA1, BRCA2, and those associated with Lynch Syndrome. The study includes a cohort of mutation carriers matched with a control group of non-carriers, collecting clinical data on treatment and outcomes both retrospectively and prospectively. Archived tumor samples will be collected for profiling, and participants may provide blood or saliva samples for genetic analysis. This research is crucial for informing clinical trials on the best management strategies for prostate cancer in high-risk patients.
Who should consider this trial
Good fit: Ideal candidates are men diagnosed with prostate cancer who are either known carriers of specific germline mutations or non-carriers.
Not a fit: Patients under 18 years of age or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for prostate cancer in patients with genetic predispositions.
How similar studies have performed: Other studies have shown success in analyzing genetic factors in cancer outcomes, but this specific approach focusing on rare mutations in prostate cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men diagnosed with PCa are eligible if: * known carriers of germline mutations associated with PCa risk OR * known non-carriers of mutations in the genes above Exclusion Criteria: * patients under 18 years of age * patients who are unable to give informed consent * patients who cannot be traced (\<6 months follow-up) or whose clinical data are not available * patients whose genetic status is unknown
Where this trial is running
Sutton, Surrey
- Institute of Cancer Research and Royal Marsden Hospital — Sutton, Surrey, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Rosalind A Eeles, PhD — Institute of Cancer Research, United Kingdom
- Study coordinator: Elizabeth C Page, MSc
- Email: elizabeth.page@icr.ac.uk
- Phone: 44 208 722 4483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.